Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pozen Continues Discussions with the FDA

By Drug Discovery Trends Editor | August 24, 2012

Pozen Inc. claims it is making progress in discussions with regulators about its experimental cardiovascular drug PA32540.

Pozen said the Food and Drug Administration appeared to be satisfied with the additional data it submitted in support of PA32540. Earlier this year, the FDA asked Pozen to do a study that would measure the bioequivalence of Pozen’s treatment compared to aspirin. The company said the FDA appears to be satisfied with its additional data even though it has not yet performed that study.

The FDA has not yet made a final determination on the additional data the company has submitted. The agency wants to confirm that PA32540 and aspirin show up in patients’ blood streams at similar rates after patients take the drugs.

The Chapel Hill, N.C., company also said it expects to file for approval of a lower-dose version of PA32540 in the first half of 2013. The FDA has agreed to give Pozen feedback as it prepares to make that filing. The lower-dose version is designated PA8140.

The drug is intended as an alternative to aspirin as a secondary treatment for the prevention of cardiovascular disease. Many people take aspirin to prevent heart problems, but long-term use of aspirin can cause ulcers. PA32540 contains aspirin and omeprazole, the active ingredient in heartburn drugs like Prilosec. The omeprazole is released as soon as the drug is taken and the aspirin is released over time.

PA32540 contains 325 milligrams of aspirin and 40 grams of omeprazole, and the company is now developing a version with 81 milligrams and aspirin and 40 milligrams of omeprazole. The FDA encouraged Pozen to study the lower-dose version and said it might only approve the larger-dose version for limited groups of patients.

Date: August 24, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE